Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01437852 · ClinicalTrials.gov registry record · Phase 1
StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
A Phase 1 study of Burns and Skin Wound, sponsored by Stratatech, a Mallinckrodt Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT01437852: Completed Phase 1 study of Burns and Skin Wound, sponsored by Stratatech, a Mallinckrodt Company.
NCT01437852 is a Phase 1 study of Burns and Skin Wound that has completed, run by Stratatech, a Mallinckrodt Company. The registered enrollment target is 30 participants, below the 82-participant average among 36 other Burns trials with a reported enrollment target (63% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01437852, a Phase 1 study of Burns and Skin Wound, has completed, sponsored by Stratatech, a Mallinckrodt Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness component of complex skin defects. The proposed study population will include patients with 3-49% Total Body Surface Area (TBSA) complex skin defects including a deep partial-thickness component resulting from thermal injury. The study has been designed to focus on the evaluation of safety and tolerability of prolonged exposure to increasing amounts of a single application of StrataGraft skin tissue, while also assessing the potential for StrataGraft tissue to promote healing of the deep partial-thickness component of these complex skin defects as an alternative to donor site harvesting and autografting. Targeted enrollment for this study is up to 30 patients with complex skin defects due to thermal burns which require surgical excision and autografting. Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving StrataGraft skin tissue that has been stored refrigerated prior to clinical use. A third cohort will receive StrataGraft skin tissue which has been stored cryopreserved and thawed in the operating room just prior to grafting.
Primary Outcome
Determination of complete wound closure of both treatment sites was evaluated at 3 months.
Conditions Studied
Interventions
- BIOLOGICAL StrataGraft Skin Tissue
Study Locations (6)
Texas
- UT-Southwestern Medical Center - Dallas
- U.S. Army Institute of Surgical Research - Fort Sam Houston
Arizona
- Maricopa Integrated Health Systems, Arizona Burn Center - Phoenix
Colorado
- University of Colorado Hospital Burn Center - Aurora
North Carolina
- Wake Forest University Baptist Medical Center - Winston-Salem
Wisconsin
- University of Wisconsin Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
What the finished NCT01437852 record still lists
NCT01437852 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 82-participant average among 36 other Burns trials with a reported enrollment target (63% lower).
The record links to 3 conditions, with Burns appearing as the primary indexed condition, and to 1 intervention - of which StrataGraft Skin Tissue is the first listed.
NCT01437852 lists 6 locations in 5 states (Texas, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT01437852 about?
NCT01437852 is a clinical study titled "StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns". The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness component of complex skin defects. The proposed study population will includ...
What is the current status of trial NCT01437852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-09. Estimated completion is 2014-10.
What conditions does trial NCT01437852 study?
This clinical trial studies the following conditions: Burns, Skin Wound, Trauma-related Wound.
What interventions are being tested in trial NCT01437852?
The interventions under investigation include: StrataGraft Skin Tissue (BIOLOGICAL).
Who is sponsoring clinical trial NCT01437852?
This trial is sponsored by Stratatech, a Mallinckrodt Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01437852 being conducted?
This trial has 6 study locations across Arizona, Colorado, North Carolina, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01437852's enrollment target sits among peer trials
30 16th of 36 higher than 20 of 36 other Burns trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes
COMPLETED · Phase 1
-
Safety of Extracellular Vesicles for Burn Wounds
COMPLETED · Phase 1
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
-
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
RECRUITING · Phase 4
-
Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia